1. Home
  2. OSRH vs KALA Comparison

OSRH vs KALA Comparison

Compare OSRH & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OSR Holdings Inc.

OSRH

OSR Holdings Inc.

HOLD

Current Price

$0.40

Market Cap

18.4M

Sector

N/A

ML Signal

HOLD

Logo KALA BIO Inc.

KALA

KALA BIO Inc.

HOLD

Current Price

$0.39

Market Cap

16.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OSRH
KALA
Founded
N/A
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.4M
16.1M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
OSRH
KALA
Price
$0.40
$0.39
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$31.50
AVG Volume (30 Days)
433.1K
553.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
41.50
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.39
$0.35
52 Week High
$4.33
$20.58

Technical Indicators

Market Signals
Indicator
OSRH
KALA
Relative Strength Index (RSI) 35.07 40.22
Support Level $0.39 $0.35
Resistance Level $0.76 $0.72
Average True Range (ATR) 0.04 0.04
MACD -0.00 0.01
Stochastic Oscillator 12.21 49.89

Price Performance

Historical Comparison
OSRH
KALA

About OSRH OSR Holdings Inc.

OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.

About KALA KALA BIO Inc.

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Share on Social Networks: